Evidence map›Paper›PMID 38100392›Full record

ReviewPLOS global public health2023

Facing the escalating burden of dengue: Challenges and perspectives.

Gathsaurie Neelika Malavige, Peter Sjö, Kavita Singh, Jean-Michel Piedagnel, Charles Mowbray, Sergio Estani, Steven Chee Loon Lim, Andre M Siquierra, Graham S Ogg, Laurent Fraisse and 1 more

Erratum issuedOpen access · goldAbstract readReview
In one paragraph

Review in PLOS global public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
19.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Economic burden of dengue in Puerto Rico, 2010-2023.Infectious diseases of poverty · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Dengue and severe dengue.Clinical microbiology reviews · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Gathsaurie Neelika MalavigeDrugs for Neglected Diseases Initiative, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-9201-0449
Peter SjöDrugs for Neglected Diseases Initiative, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-6768-0536
Kavita SinghDrugs for Neglected Diseases Initiative, Geneva, Switzerland.
Jean-Michel PiedagnelDrugs for Neglected Diseases Initiative, Geneva, Switzerland.
Charles MowbrayDrugs for Neglected Diseases Initiative, Geneva, Switzerland.
Sergio EstaniDrugs for Neglected Diseases Initiative, Geneva, Switzerland.
Steven Chee Loon LimMinistry of Health, Putrajaya, Malaysia.
Andre M SiquierraFiocruz, Rio de Janeiro, Brazil.
Graham S OggMRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.ORCID https://orcid.org/0000-0002-3097-045X
Laurent FraisseDrugs for Neglected Diseases Initiative, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-1530-3894
Isabela RibeiroDrugs for Neglected Diseases Initiative, Geneva, Switzerland.
Drugs for Neglected Diseases Initiative · CHFundação Oswaldo Cruz · BRMinistry of Health · MYUniversity of Oxford · GB

Funding

Medical Research Council MC_UU_00008/5Medical Research Council MC_UU_00036/2
6 · The paper itself

Abstract

Dengue is the most rapidly emerging mosquito-borne infection and, due to climate change and unplanned urbanization, it is predicted that the global burden of dengue will rise further as the infection spreads to new geographical locations. Dengue-endemic countries are often unable to cope with such increases, with health care facilities becoming overwhelmed during each dengue season. Furthermore, although dengue has been predominantly a childhood illness in the past, it currently mostly affects adults in many countries, with higher incidence of severe disease and mortality rates in pregnant women and in those with comorbidities. As there is currently no specific treatment for dengue and no early biomarker to identify those who will progress to develop vascular leakage, all individuals with dengue are closely monitored in case they need fluid management. Furthermore, diagnosing patients with acute dengue is challenging due to the similarity of clinical symptoms during early illness and poor sensitivity and specificity of point-of-care diagnostic tests. Novel vector control methods, such as the release of Wolbachia-infected mosquitoes, have shown promising results by reducing vector density and dengue incidence in clinical trial settings. A new dengue vaccine, TAK-003, had an efficacy of 61.2% against virologically confirmed dengue, 84.1% efficacy against hospitalizations and a 70% efficacy against development of dengue haemorrhagic fever (DHF) at 54 months. While vaccines and mosquito control methods are welcome, they alone are unlikely to fully reduce the burden of dengue, and a treatment for dengue is therefore essential. Several novel antiviral drugs are currently being evaluated along with drugs that inhibit host mediators, such as mast cell products. Although viral proteins such as NS1 contribute to the vascular leak observed in severe dengue, the host immune response to the viral infection also plays a significant role in progression to severe disease. There is an urgent need to discover safe and effective treatments for dengue to prevent disease progression.

Identifiers

PMID38100392
PMCPMC10723676
OpenAlexW4389780522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.